Effects of Soy Isoflavone on Hepatic Steatosis in High Fat-induced Rats

Overview

Journal J Clin Biochem Nutr

Specialty Biochemistry

Date 2017 Sep 29

PMID 28955124

Citations 22

Authors

Huanhuan Liu

Huijia Zhong

Liang Leng

Zhuoqin Jiang

Affiliations

Soon will be listed here.

Abstract

Soy isoflavone has benefits for metabolic syndrome but the mechanism is not completely understood. This study was designed to determine the effects of soy isoflavone on hepatic fat accumulation in non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet (HFD). Sprague-Dawley rats were administrated with a normal fat diet (control), HFD (NAFLD model), HFD with 10 or 20 mg/kg soy isoflavone daily for 12 weeks. Hepatic and serum lipid contents, liver histopathological examination, serum alanine transaminase (ALT), protein and mRNA expression of sterol regulatory element binding protein (SREBP)-1c, fatty acid synthase (FAS), peroxisome proliferator-activated receptor (PPAR) α were assayed respectively. Our study found that soy isoflavone reduced HFD-induced lipid accumulation in liver, serum ALT and improved liver lobule structure. In addition, the expression of SREBP-1c and FAS was lower, whereas protein level of PPARα was higher in two soy isoflavone groups than that of the HFD group. Collectively, these results demonstrate that soy isoflavone is capable of alleviating hepatic steatosis and delaying the progression of NAFLD via inhibiting lipogenesis and promoting fatty acid oxidation in liver.

Citing Articles

The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A.

Neshatbini Tehrani A, Hatami B, Helli B, Yari Z, Daftari G, Salehpour A Sci Rep. 2024; 14(1):5134.

PMID: 38429385 PMC: 10907727. DOI: 10.1038/s41598-024-55747-6.

Nutritional Genomics in Nonalcoholic Fatty Liver Disease.

Vasconcellos C, Ferreira O, Lopes M, Ribeiro A, Vasques J, Guerreiro C Biomedicines. 2023; 11(2).

PMID: 36830856 PMC: 9953045. DOI: 10.3390/biomedicines11020319.

Preclinical and clinical evidence for the treatment of non-alcoholic fatty liver disease with soybean: A systematic review and meta-analysis.

Li Y, Deng X, Guo X, Zhang F, Wu H, Qin X Front Pharmacol. 2023; 14:1088614.

PMID: 36762106 PMC: 9907442. DOI: 10.3389/fphar.2023.1088614.

Nutraceuticals in Brown Adipose Tissue Activation.

Armani A, Feraco A, Camajani E, Gorini S, Lombardo M, Caprio M Cells. 2022; 11(24).

PMID: 36552762 PMC: 9776638. DOI: 10.3390/cells11243996.

Association between flavonoid and subclasses intake and metabolic associated fatty liver disease in U.S. adults: Results from National Health and Nutrition Examination Survey 2017-2018.

Tong J, Zeng Y, Xie J, Xiao K, Li M, Cong L Front Nutr. 2022; 9:1074494.

PMID: 36532560 PMC: 9751205. DOI: 10.3389/fnut.2022.1074494.

References

Anthony M, Clarkson T, Hughes Jr C, Morgan T, Burke G . Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutr. 1996; 126(1):43-50. DOI: 10.1093/jn/126.1.43. View

Armstrong M, Adams L, Canbay A, Syn W . Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2013; 59(3):1174-97. DOI: 10.1002/hep.26717. View

Adams L, Lindor K . Nonalcoholic fatty liver disease. Ann Epidemiol. 2007; 17(11):863-9. DOI: 10.1016/j.annepidem.2007.05.013. View

Takagi A, Kano M, Kaga C . Possibility of breast cancer prevention: use of soy isoflavones and fermented soy beverage produced using probiotics. Int J Mol Sci. 2015; 16(5):10907-20. PMC: 4463682. DOI: 10.3390/ijms160510907. View

Doege H, Grimm D, Falcon A, Tsang B, Storm T, Xu H . Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem. 2008; 283(32):22186-92. PMC: 2494916. DOI: 10.1074/jbc.M803510200. View

Wong R, Aguilar M, Cheung R, Perumpail R, Harrison S, Younossi Z . Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2014; 148(3):547-55. DOI: 10.1053/j.gastro.2014.11.039. View

Kurrat A, Blei T, Kluxen F, Mueller D, Piechotta M, Soukup S . Lifelong exposure to dietary isoflavones reduces risk of obesity in ovariectomized Wistar rats. Mol Nutr Food Res. 2015; 59(12):2407-18. DOI: 10.1002/mnfr.201500240. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Jha H, von Recklinghausen G, Zilliken F . Inhibition of in vitro microsomal lipid peroxidation by isoflavonoids. Biochem Pharmacol. 1985; 34(9):1367-9. DOI: 10.1016/0006-2952(85)90672-0. View

10.

Sinn D, Kang D, Chang Y, Ryu S, Gu S, Kim H . Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 2016; 66(2):323-329. DOI: 10.1136/gutjnl-2016-311854. View

11.

Ji G, Yang Q, Hao J, Guo L, Chen X, Hu J . Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol. 2011; 11(6):762-8. DOI: 10.1016/j.intimp.2011.01.036. View

12.

Lagari V, Levis S . Phytoestrogens for menopausal bone loss and climacteric symptoms. J Steroid Biochem Mol Biol. 2012; 139:294-301. DOI: 10.1016/j.jsbmb.2012.12.002. View

13.

Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L . Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016; 150(5):1147-1159.e5. DOI: 10.1053/j.gastro.2016.01.038. View

14.

Wang Y, Viscarra J, Kim S, Sul H . Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015; 16(11):678-89. PMC: 4884795. DOI: 10.1038/nrm4074. View

15.

Pawlak M, Lefebvre P, Staels B . Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2014; 62(3):720-33. DOI: 10.1016/j.jhep.2014.10.039. View

16.

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

17.

Brunt E . Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010; 7(4):195-203. DOI: 10.1038/nrgastro.2010.21. View

18.

Shin E, Lee H, Cho S, Park H, Lee S, Lee T . Genistein downregulates SREBP-1 regulated gene expression by inhibiting site-1 protease expression in HepG2 cells. J Nutr. 2007; 137(5):1127-31. DOI: 10.1093/jn/137.5.1127. View

19.

Sankar P, Zachariah B, Vickneshwaran V, Jacob S, Sridhar M . Amelioration of oxidative stress and insulin resistance by soy isoflavones (from Glycine max) in ovariectomized Wistar rats fed with high fat diet: the molecular mechanisms. Exp Gerontol. 2015; 63:67-75. DOI: 10.1016/j.exger.2015.02.001. View

20.

Li M, Ye T, Wang X, Li X, Qiang O, Yu T . Effect of Octreotide on Hepatic Steatosis in Diet-Induced Obesity in Rats. PLoS One. 2016; 11(3):e0152085. PMC: 4803296. DOI: 10.1371/journal.pone.0152085. View